Abstract
Type I interferons (IFNs) represent a group of cytokines that act through a common receptor composed by two chains (IFNAR-1 and IFNAR-2). Several in vitro and in vivo studies showed a potent antitumor activity induced by these cytokines. IFN-, the first cytokine to be produced by recombinant DNA technology, has emerged as an important regulator of cancer cell growth and differentiation, affecting cellular communication and signal transduction pathways. IFN-, is currently the most used cytokine in the treatment of cancer. However, the potential anti-tumour activity of IFN- is limited by the activation of tumour resistance mechanisms. This article reviews the current knowledge about the antitumor activity of type I IFNs, focusing on new potential strategies able to strengthen the antitumor activity of these cytokines.
Keywords: Type I interferons, interferon-alpha, interferon-beta, STATs, mTOR, pegylated interferons, farnesyltransferase inhibitors, EGF-R, cytokine, antitumor activity
Protein & Peptide Letters
Title:Type I Interferons: Ancient Peptides with Still Under-Discovered Anti-Cancer Properties
Volume: 20 Issue: 4
Author(s): Michele Caraglia, Alessandra Dicitore, Monica Marra, Sara Castiglioni, Luca Persani, Pasquale Sperlongano, Pierosandro Tagliaferri, Alberto Abbruzzese and Giovanni Vitale
Affiliation:
Keywords: Type I interferons, interferon-alpha, interferon-beta, STATs, mTOR, pegylated interferons, farnesyltransferase inhibitors, EGF-R, cytokine, antitumor activity
Abstract: Type I interferons (IFNs) represent a group of cytokines that act through a common receptor composed by two chains (IFNAR-1 and IFNAR-2). Several in vitro and in vivo studies showed a potent antitumor activity induced by these cytokines. IFN-, the first cytokine to be produced by recombinant DNA technology, has emerged as an important regulator of cancer cell growth and differentiation, affecting cellular communication and signal transduction pathways. IFN-, is currently the most used cytokine in the treatment of cancer. However, the potential anti-tumour activity of IFN- is limited by the activation of tumour resistance mechanisms. This article reviews the current knowledge about the antitumor activity of type I IFNs, focusing on new potential strategies able to strengthen the antitumor activity of these cytokines.
Export Options
About this article
Cite this article as:
Caraglia Michele, Dicitore Alessandra, Marra Monica, Castiglioni Sara, Persani Luca, Sperlongano Pasquale, Tagliaferri Pierosandro, Abbruzzese Alberto and Vitale Giovanni, Type I Interferons: Ancient Peptides with Still Under-Discovered Anti-Cancer Properties, Protein & Peptide Letters 2013; 20 (4) . https://dx.doi.org/10.2174/0929866511320040005
DOI https://dx.doi.org/10.2174/0929866511320040005 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Src Tyrosine Kinase Inhibition Suppresses Lymphangiogenesis In Vitro and In Vivo
Current Cancer Drug Targets Phospholipase A2 Isoforms as Novel Targets for Prevention and Treatment of Inflammatory and Oncologic Diseases
Current Drug Targets Mammalian Cell Competitions, Cell-in-Cell Phenomena and Their Biomedical Implications.
Current Molecular Medicine Sunitinib (SUTENT, SU11248) Suppresses Tumor Growth and Induces Apoptosis in Xenograft Models of Human Hepatocellular Carcinoma
Current Cancer Drug Targets Developing FGFR4 Inhibitors As Potential Anti-Cancer Agents Via In Silico Design, Supported by In Vitro and Cell-Based Testing
Current Medicinal Chemistry The Role of EGFR-Met Interactions in the Pathogenesis of Glioblastoma and Resistance to Treatment
Current Cancer Drug Targets Therapeutic Targeting of Cancers with Loss of PTEN Function
Current Drug Targets The ABCA2 Transporter: Intracellular Roles in Trafficking and Metabolism of LDL-Derived Cholesterol and Sterol-Related Compounds
Current Drug Metabolism Two Novel Heparin-binding Vascular Endothelial Growth Factor Splices, L-VEGF144 and L-VEGF138, are Expressed in Human Glioblastoma Cells
Current Neurovascular Research EphA2-Dependent Molecular Targeting Therapy for Malignant Tumors
Current Cancer Drug Targets Huntingtons Disease: New Frontiers for Molecular and Cell Therapy
Current Drug Targets Inhibition of the Tissue Factor Coagulation Pathway
Current Vascular Pharmacology Removing Protein Aggregates: The Role of Proteolysis in Neurodegeneration
Current Medicinal Chemistry Adrenergic Action in Breast Cancer
Current Cancer Therapy Reviews Breast Cancer: Current Developments in Molecular Approaches to Diagnosis and Treatment
Recent Patents on Anti-Cancer Drug Discovery Planar Bioadhesive Microdevices: A New Technology for Oral Drug Delivery
Current Pharmaceutical Biotechnology The Effect of Chemotherapy/Radiotherapy on Cancerous Pattern Recognition by NK Cells
Current Medicinal Chemistry Mycotherapy of Cancer: An Update on Cytotoxic and Antitumor Activities of Mushrooms, Bioactive Principles and Molecular Mechanisms of their Action
Current Topics in Medicinal Chemistry Protein Extracts from Somaclonal Mistletoe (Viscum Album L.) Callus with Increased Tumor Cytotoxic Activity in Vitro
Current Bioactive Compounds The Role of Snail in EMT and Tumorigenesis
Current Cancer Drug Targets